Back to search results

Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS) for PTSD

This study is testing a personalized brain stimulation treatment called Personalized repetitive transcranial magnetic stimulation (PrTMS) for military service members and veterans with Post-Traumatic Stress Disorder (PTSD). Unlike other methods, PrTMS uses your unique brainwave patterns (from an EEG test) to tailor the treatment specifically for you. You'll be randomly assigned to receive either the active PrTMS treatment or a sham (inactive) treatment for 6 weeks. Researchers will look at how your PTSD symptoms change, as well as your mood, sleep, and overall well-being. To join, you must be a veteran or military member, aged 18 or older, with a confirmed PTSD diagnosis and specific symptom scores. The study aims to see if this personalized approach offers better and longer-lasting relief for PTSD.

Study design
This is a randomized, double-blind study where 100 participants will receive either active PrTMS or a sham treatment. The study aims to compare the personalized treatment to a non-personalized approach.
What's involved
You would receive 30-minute treatment sessions 5 days a week for 6 weeks. Researchers will also track your symptoms, mood, sleep, and well-being using various assessments and wearable devices.
Compensation
Not stated in the trial record.
Follow-up
After the 6-week treatment, researchers will continue to assess you for 6 months to see how long the benefits last.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07526285

Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS) for Treatment of Post-Traumatic Stress Disorder (PTSD)

Not Yet Recruiting
NAAges 18+InterventionalTreatment
Massachusetts General Hospital
~100 participants
Updated 2026-04-13 on ClinicalTrials.gov
What's tested:Transcranial Magnetic StimulationTranscranial Magnetic Stimulation Sham

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Measured over At baseline and the end of treatment at Week 6.

Conditions

Posttraumatic Stress Disorder (PTSD)

Explore related trials

Post-Traumatic Stress Disorder

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Sofia E Matta, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

Joseph Bonvie, PsyD
[email protected]
8572053407
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Reserve or former member of the military (veteran status)
Age 18 years or older
Primary diagnosis of post-traumatic stress disorder (PTSD) confirmed by the - Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5) score ≥ 33, indicating clinically significant PTSD symptoms
Proficient in English (spoken and written) to ensure understanding of study procedures and informed consent

Exclusion

History of open-skull traumatic brain injury
Clinically significant seizure disorder or history of manic episodes
Neurological conditions associated with increased risk (e.g., increased intracranial pressure, brain lesions, stroke, cerebral aneurysm)
Electroencephalogram (EEG) abnormalities suggesting elevated seizure risk
Repetitive transcranial magnetic stimulation (rTMS) within 3 months prior to screening
Current use of antipsychotic or anticonvulsant medications
Presence of intracranial implants or non-removable metal in or near the head (excluding the mouth)
Clinically significant or unstable medical conditions, including active suicidal ideation
Uncontrolled medical illness (e.g., thyroid, hepatic, cardiac, pulmonary, or renal disease)
Initiation of PTSD-specific treatment within the past 4 weeks (participants on a stable regimen may be eligible)
Pregnancy (for women of childbearing potential)
Any condition that, in the opinion of the investigator, may interfere with study participation or completion

What this trial measures

  • Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)At baseline and the end of treatment at Week 6.

    The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a structured interview and gold standard for diagnosing and assessing PTSD in clinical and research settings. It assesses current or lifetime PTSD based on DSM-5 criteria and measures symptom severity across the 20 PTSD symptoms, including the dissociative subtype, in relation to a single index traumatic event. Total severity scores range from 0 to 80, with higher scores indicating worse PTSD symptom severity.